Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Shares Up 0.4% - Still a Buy?

Shares of Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF - Get Free Report) shot up 0.4% during trading on Monday . The stock traded as high as $27.00 and last traded at $27.00. 100 shares changed hands during trading, a decline of 75% from the average session volume of 400 shares. The stock had previously closed at $26.90.

Wall Street Analyst Weigh In

Separately, Barclays raised shares of Swedish Orphan Biovitrum AB (publ) to a "strong-buy" rating in a research note on Wednesday, January 8th.

Swedish Orphan Biovitrum AB (publ) Trading Up 0.9 %

The company has a market capitalization of $10.32 billion, a PE ratio of 27.88 and a beta of 0.54. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.62 and a current ratio of 0.91. The business has a fifty day moving average price of $28.69 and a 200 day moving average price of $29.02.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.